On fast track to defeat cancer, Peninsula startup lands $108M from A-list investors

The company, launched in spring 2019 by veterans of Pfizer's now-shuttered cancer immunotherapy research center in South San Francisco, expects to grow to about 60 employees as it takes its first drug into its first clinical trial late next year.